Antibodies to DNA

New England Journal of Medicine

Volumn 338, Issue 19, 1998, Pages 1359-1368

  Hahn, Bevra Hannahs ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; AUTOANTIBODY; B7 ANTIGEN; CARDIOLIPIN ANTIBODY; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; COLLAGEN; COMPLEMENT; CYTOTOXIC AGENT; DNA ANTIBODY; DOUBLE STRANDED DNA; FC RECEPTOR; GLUCOCORTICOID; HEPARAN SULFATE; HLA ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LAMININ; NUCLEOSIDE; NUCLEOTIDE; OLIGONUCLEOTIDE; RNA; SINGLE STRANDED DNA; SMALL NUCLEAR RNA; T LYMPHOCYTE RECEPTOR; UNINDEXED DRUG;

ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; BASE PAIRING; DNA PROTEIN COMPLEX; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANTIBODIES, ANTINUCLEAR; HUMANS; IMMUNOSUPPRESSION; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0032493059     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199805073381906     Document Type: Review

References (77)

1. Holborow J, Weir DM, Johnson GD. A serum factor in lupus erythematosus with affinity for tissue nuclei. BMJ 1957;2:732-4.
2. Ceppellini R, Polli E, Celada F. A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus. Proc Soc Exp Biol Med 1957; 96:572-4.
3. Robbins WC, Holman HR, Deicher H, Kunkel HG. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol Med 1957;96:575-9.
4. Rothfield NF, Stollar BD. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 1967; 46:1785-94.
5. Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 1968;161:904-6.
6. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533-8.
7. Stollar BD. Molecular analysis of anti-DNA antibodies. FASEB J 1994; 8:337-42.
8. Kalsi JK, Martin AC, Hirabayashi Y, et al. Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Mol Immunol 1996;33:471-83.
9. Herrmann M, Winkler TH, Fehr H, Kalden JR. Preferential recognition of specific DNA motifs by anti-double-stranded DNA autoantibodies. Eur J Immunol 1995;25:1897-904.
10. Pisetsky DS, Jelinek DF, McAnally LM, Reich CF, Lipsky PE. In vitro autoantibody production by normal adult and cord blood B cells. J Clin Invest 1990;85:899-903.
11. Taki S, Hirose S, Kinoshita K, et al. Somatically mutated IgG anti-DNA antibody clonally related to germ-line encoded IgM anti-DNA antibody. Eur J Immunol 1992;22:987-92.
12. Diamond B, Katz JB, Paul E, Aranow C, Lustgarten D, Scharff MD. The role of somatic mutation in the pathogenic anti-DNA response. Annu Rev Immunol 1992;10:731-57.
13. Schwartz RS, Stollar BD. Origins of anti-DNA autoantibodies. J Clin Invest 1985;75:321-7.
14. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994;94:184-92.
15. Reeves WH, Satoh M, Wang J, Chou CH, Ajmani AK. Systemic lupus erythematosus: antibodies to DNA, DNA-binding proteins, and histones. Rheum Dis Clin North Am 1994;20:1-28.
16. Mohan C, Datta SK. Lupus: key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol 1995;77:209-20.
17. Brinkman K, Termaat R, Berden JH, Smeenk RJ. Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol Today 1990;11:232-4.
18. Lefkowith JB, Kiehl M, Rubenstcin J, et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J Clin Invest 1996;98:1373-80.
19. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977;59:90-6.
20. Quismorio FP Jr. Clinical application of serologic abnormalities in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins, 1997:925-42
21. Smeenk RJT, van den Brink HG, Brinkman K, Termaat RM, Berden JHM, Swaak AJG. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol Int 1991;11:101-7.
22. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term prospective study. Arthritis Rheum 1990;33:634-43.
23. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271-7.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
25. Weinstein A, Bordwell B, Stone B, Tibbetts C, Rothfield NF. Antibodies to native DNA and serum complement (C3) levels: application to diagnosis and classification of systemic lupus erythematosus. Am J Med 1983; 74:206-16.
26. Perez-Gutthann S, Petri M, Hochberg MC. Comparison of different methods of classifying patients with systemic lupus erythematosus. J Rheumatol 1991;18:1176-9.
27. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-9.
28. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996;39:370-8.
29. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 1991;34:937-44.
30. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serological features. Am J Med 1979;66:210-5.
31. Putterman C, Kuo P, Diamond B. The structure and derivation of antibodies and autoantibodies. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins, 1997:383-96.
32. Zouali M. The structure of human lupus anti-DNA antibodies. Methods 1997;11:27-35.
33. Pyun EH, Pisetsky DS, Gilkeson GS. The fine specificity of monoclonal anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. J Autoimmun 1993;6:11-26.
34. Rekvig OP, Fredriksen K, Brannsether B, Moens U, Sundsfjord A, Traavik T. Antibodies to eukaryotic, including autologous, native DNA are produced during BK virus infection, but not after immunization with non-infectious BK DNA. Scand J Immunol 1992;36:487-95.
35. Desai DD, Krishnan MR, Swindle JT, Marion TN. Antigen-specific induction of antibodies against native mammalian DNA in nonautoimmune mice. J Immunol 1993;151:1614-26.
36. Satoh M, Kumar A, Kanwar YS, Reeves WH. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci U S A 1995;92:10934-8.
37. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-81.
38. Theofilopoulos AN. The basis of autoimmunity. II. Genetic predisposition. Immunol Today 1995;16:150-9.
39. Tsao BP, Cantor RM, Kalunian KC, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997;99:725-31.
40. James JA, Gross T, Scoficld RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995;181:453-61.
41. Hemmer B, Fleckenstein BT, Vergelli M, et al. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 1997;185:1651-9.
42. Casciola-Rosen L, Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 1997;6:175-80.
43. Emlen W, Neibur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-92.
44. Mahmoudi M, Denomme GA, Edwards JY, Bell DA, Cairns E. The role of the immunoglobulin heavy chain in human anti-DNA antibody binding specificity. Arthritis Rheum 1995;38:389-95.
45. van Es JH, Gmelig Meyling FJH, van de Akker WRM, Aanstoot H, Derksen RHWM, Logtenberg T. Somatic mutations in the variable regions of a human IgG anti-double-stranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus. J Exp Med 1991;173:461-70.
46. Winkler TH, Fehr H, Kalden JR. Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol 1992;22:1719-28.
47. Radic MZ, Weigert MG. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994;12:487-520.
48. Radic MZ, Mascelli MA, Erikson J, Shan H, Weigert M. Ig H and L chain contributions to autoimmune specificities. J Immunol 1991;146: 176-82.
49. Ohnishi K, Ebling FM, Mitchell B, Singh RR, Hahn BH, Tsao BP. Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int Immunol 1994;6: 817-30.
50. Tsao BP, Hahn BH. Transgenic mice as models for studying the regulation and role of anti-DNA antibodies in murine lupus. Immunomethods 1992;1:185-90.
51. Ehrenstein MR, Katz DR, Griffiths MH, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995;48:705-11.
52. Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 1997;51:270-6.
53. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-54.
54. Duits AJ, Bootsma H, Derksen RHWM, et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995;39:1832-6.
55. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
56. Suzuki N, Harada T, Mizushima Y, Sakane T. Possible pathogenic role of cationic anti-DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus. J Immunol 1993;151:1128-36.
57. Kalunian KC, Panosian-Sahakian N, Ebling FM, et al. Idiotypic characteristics of immunoglobulins associated with systemic lupus erythematosus: studies of antibodies deposited in glomeruli of humans. Arthritis Rheum 1989;32:513-22.
58. Isenberg DA, Williams W, Axford J, et al. Comparison of DNA antibody idiotypes in human sera: an international collaborative study of 19 idiotypes from 11 different laboratories. J Autoimmun 1990;3:393-414.
59. Suzuki M, Hatakeyama A, Kameoka J, et al. Anti-DNA idiotypes deposited in renal glomeruli of patients with lupus nephritis. Am J Kidney Dis 1991;18:232-9.
60. Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994;8:1296-301.
61. Alarcon-Segovia D, Llorente L. Antibody penetration into living cells. IV. Different effects of anti-native DNA and anti-ribonucleoprotein IgG on the cell cycle of activated T gamma cells. Clin Exp Immunol 1983;52:365-71.
62. Koren E, Koscec M, Wolfson-Reichlin M, et al. Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. J Immunol 1995;154: 4857-64.
63. Yanase K, Smith RM, Puccetti A, Jarett L, Madaio MP. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997;100:25-31.
64. van Bruggen MC, Kramers C, Hylkema MN, Smeenk RJ, Berden JH. Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis: a longitudinal study on plasma and glomerular eluates in MRL/1 mice. Clin Exp Immunol 1996;105:132-9.
65. Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990;33:1216-25.
66. Williams WM, Staines NA, Muller S, Isenberg DA. Human T cell responses to autoantibody variable region peptides. Lupus 1995;4:464-71.
67. Singh RR, Ebling FM, Sercarz EE, Hahn BH. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995;96:2990-6.
68. Gauthier VJ, Emlen JW. Immune complexes in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997:207-20.
69. Krych M, Atkinson JP, Holers VM. Complement receptors. Curr Opin Immunol 1992;4:8-13.
70. Abdou NI, Wall H, Lindsley HB, Halsey JF, Suzuki T. Network theory in autoimmunity: in vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J Clin Invest 1981;67:1297-304.
71. Williams RC Jr, Malone CC, Huffman GR, et al. Active systemic lupus erythematosus is associated with depletion of the natural generic anti-idiotype (anti-F(ab′)2) system. J Rheumatol 1995;22:1075-85.
72. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/ NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987;138:3247-53.
73. Gao CL, Li BA, Chen CZ, Yu YT, Yuan P, Song JC. Clinical trials of immunoadsorbcnt in systemic lupus erythematosus therapy. Artif Organs 1995;19:468-9.
74. Silvestris F, D'Amore O, Cafforio P, Savino L, Dammacco F. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Immunol 1996;104:Suppl 1:91-7.
75. Hepburn B, Furie R, Cash J, et al. Reduction of anti-dsDNA antibodies using LJP 394 in patients with lupus. Arthritis Rheum 1996;39:Suppl: S307. abstract.
76. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black X New Zealand white mice: response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
77. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.